We are live on ! Find out more
CLVS

Clovis Oncology, Inc.

Delisted

CLVS was delisted on the 20th of December, 2022.

2 hedge funds and large institutions have $520K invested in Clovis Oncology, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% less capital invested

Capital invested by funds: $525K → $520K (-$4.37K)

87% less funds holding

Funds holding: 152 (-13)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 13

Holders
2
Holders Change
-13
Holders Change %
-86.67%
% of All Funds
0.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
1
Reduced
Closed
13
Calls
Puts
Net Calls
Net Calls Change

CLVS Hedge Fund Activity: Q1 2023 in Review

2 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q1 2023, worth a combined $520K — down 0.83% from $525K a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CLVS and 0 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Resources Management Corp, adding an estimated $510K. The largest seller was IFP Advisors, exiting entirely with an estimated $479K sold.

  • 2 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q1 2023, down from 15 in Q4 2022.
  • Funds reported $520K of Clovis Oncology, Inc. stock for Q1 2023, down 0.83% quarter-over-quarter.
  • 0 funds opened new Clovis Oncology, Inc. positions in Q1 2023 and 13 closed out, a net change of -13 holders.
  • The largest Clovis Oncology, Inc. buyer in Q1 2023 was Resources Management Corp, an estimated $510K added.
  • The largest Clovis Oncology, Inc. seller in Q1 2023 was IFP Advisors, an estimated $479K sold.

Based on aggregated 13F filings for Q1 2023.